Dr. Angela Talley is Senior Vice President of Clinical Development at Spero Therapeutics and clinical lead for the tebipenem HBr program. Dr. Talley is an Infectious Disease physician with over 15 years of experience in anti-infective clinical research and drug development in both academia and industry. Prior to joining Spero Therapeutics in 2018, Dr. Talley served as Executive Director of Clinical Development for Anti-Infectives at Allergan, plc, where she led clinical development activities for multiple anti-infective programs in Phase I-IV development since 2015 and prior to this held similar roles for related clinical development programs at Cerexa, Inc (a subsidiary of Forest Laboratories, later acquired by Actavis, plc). During her time in the industry, she has established a successful track record for clinical development and regulatory strategy, including multiple successful NDA/sNDA approvals. She received her M.D. from Mount Sinai School of Medicine with research honors, and subsequently completed internship and residency training in Internal Medicine at Columbia-Presbyterian Medical Center and Infectious Disease Fellowship training at the University of Washington. Early in her career she was appointed as a Howard Hughes Medical Research Institute Research Scholar and received a Fellowship award for her work in the Laboratory of Parasitic Diseases, NIAID. She held clinical faculty appointments at Columbia University (HIV Vaccines Trial Unit) and later at the University of Washington, where her research focus was on novel malaria therapeutics and malaria vaccine development before transitioning to Industry.